Arcus Biosciences Inc (RCUS)
15.07
+0.14
(+0.94%)
USD |
NYSE |
May 31, 16:00
15.07
0.00 (0.00%)
After-Hours: 20:00
Arcus Biosciences Research and Development Expense (Quarterly): 109.00M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 109.00M |
December 31, 2023 | 93.00M |
September 30, 2023 | 82.00M |
June 30, 2023 | 84.00M |
March 31, 2023 | 81.00M |
December 31, 2022 | 80.00M |
September 30, 2022 | 77.00M |
June 30, 2022 | 70.00M |
March 31, 2022 | 61.00M |
December 31, 2021 | 50.59M |
September 30, 2021 | 71.25M |
June 30, 2021 | 68.77M |
March 31, 2021 | 66.39M |
December 31, 2020 | 48.36M |
September 30, 2020 | 51.80M |
Date | Value |
---|---|
June 30, 2020 | 35.69M |
March 31, 2020 | 23.14M |
December 31, 2019 | 20.69M |
September 30, 2019 | 17.24M |
June 30, 2019 | 25.00M |
March 31, 2019 | 15.55M |
December 31, 2018 | 11.44M |
September 30, 2018 | 12.86M |
June 30, 2018 | 13.70M |
March 31, 2018 | 11.65M |
December 31, 2017 | 12.15M |
September 30, 2017 | 21.44M |
June 30, 2017 | 7.834M |
March 31, 2017 | 5.804M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
17.24M
Minimum
Sep 2019
109.00M
Maximum
Mar 2024
60.80M
Average
67.58M
Median
Research and Development Expense (Quarterly) Benchmarks
Bristol-Myers Squibb Co | 2.695B |
Gilead Sciences Inc | 3.95B |
Merck & Co Inc | 3.992B |
Pfizer Inc | 2.493B |
Alnylam Pharmaceuticals Inc | 261.00M |